Weekly

Weekly

#issue24 #podcast
The Pseudonymous Meritocracy with Bored Elon Musk
The Pseudonymous Meritocracy with Bored Elon Musk
Listen to this episode from The Deep End on Spotify. Bored Elon Musk  (one of Twitter's largest pseudonyms with 1.7 million followers) joins us to discuss the nature of pseudonyms and his investment activity. We also chat about the metaverse, the pseudonymous tech stack, the future of deep fakes, and much more.Pseudonyms are interesting because they are inherently meritocratic. Bias isn't possible because nobody knows who you really are. As the internet becomes more crypto-native and employment becomes more fluid, pseudonyms will only continue to rise in popularity. Already, DAOs are full of contributors that use pseudonyms.It's worth noting that pseudonymity is not anonymity. A pseudonym can build reputation that persists through interactions.Bored Elon is trying to make sure that as one of the first major pseudonyms, he sets the right example with his online reputation. Besides posting memes or tweeting fake startup ideas, Bored Elon is spending a lot of time investing in real companies with the bored fund. Many founders are happy to take his money without knowing who he is - a future where we can interact based on the merits of our activity over our identity is one that will benefit many.For full show notes, links, RSVPs to live podcast recordings and more, visit thedeepend.substack.com
·open.spotify.com·
The Pseudonymous Meritocracy with Bored Elon Musk
#175 - Matt Kaeberlein, Ph.D.: The biology of aging, rapamycin, and other interventions that target the aging process - Peter Attia
#175 - Matt Kaeberlein, Ph.D.: The biology of aging, rapamycin, and other interventions that target the aging process - Peter Attia
“I don't think I will ever understand aging fully. And I don't think the field will. … But I also believe that we don't have to understand it fully to be able to have an impact on the biology of aging through interventions.” —Matt Kaeberlein
·peterattiamd.com·
#175 - Matt Kaeberlein, Ph.D.: The biology of aging, rapamycin, and other interventions that target the aging process - Peter Attia